U.S. Markets closed

Exicure, Inc. (XCUR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8000-0.0400 (-2.17%)
At close: 4:00PM EDT

1.8700 +0.07 (3.89%)
After hours: 5:45PM EDT

Exicure, Inc.

2430 North Halsted Street
Chicago, IL 60614
United States
847 673 1700
http://www.exicuretx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees63

Key Executives

NameTitlePayExercisedYear Born
Dr. Chad A. Mirkin Ph.D.Co-Founder & Director165kN/A1964
Dr. David A. GiljohannCEO, Interim Principal Financial Officer, Corp. Sec. & Director785.46kN/A1981
Dr. Matthias G. Schroff Ph.D.Chief Operating Officer476.31kN/A1968
Dr. Douglas E. FeltnerChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.

Corporate Governance

Exicure, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.